Kevin Scott Brandt

US Patent:

6455039, Sep 24, 2002

Filed:

Jan 30, 2001

Appl. No.:

09/774377

Inventors:

Cynthia Ann Tripp - Ft. Collins CO
Kevin S. Brandt - Windsor CO
Nancy Wisnewski - Ft. Collins CO

Assignee:

Heska Corporation - Ft. Collins CO

International Classification:

C12Q 168

US Classification:

4241301, 4241391, 4241501, 5303871, 5303881, 5303879

Abstract:

The present invention relates to parasitic helminth macrophage migration inhibitory factor (MIF) proteins; to parasitic helminth MIF nucleic acid molecules, including those that encode such MIF proteins; to antibodies raised against such MIF proteins; and to compounds that inhibit parasitic helminth MIF activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.

US Patent:

6638744, Oct 28, 2003

Filed:

Jul 31, 2001

Appl. No.:

09/919060

Inventors:

Nancy Wisnewski - Fort Collins CO
Kevin S. Brandt - Fort Collins CO

Assignee:

Heska Corporation - Fort Collins CO

International Classification:

C12N 902

US Classification:

435189, 4352523, 4353201, 4352351, 435 711, 536 232, 536 231, 530350

Abstract:

The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.

US Patent:

6664090, Dec 16, 2003

Filed:

May 2, 2000

Appl. No.:

09/403942

Inventors:

Gary M. Silver - Fort Collins CO
Nancy Wisnewski - Fort Collins CO
Kevin S. Brandt - Ft Collins CO

Assignee:

Heska Corporation - Fort Collins CO

International Classification:

C12N 918

US Classification:

435197, 435183, 435196, 435 19, 4353201, 435 692, 4352523, 435325, 536 231, 536 232, 536 2431, 530350

Abstract:

The present invention relates to arthropod esterase proteins; to arthropod esterase nucleic acid molecules, including those that encode such esterase proteins; to antibodies raised against such esterase proteins; and to other compounds that inhibit arthropod esterase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from hematophagous arthropod infestation.

US Patent:

7223578, May 29, 2007

Filed:

Oct 2, 2003

Appl. No.:

10/679140

Inventors:

Nancy Wisnewski - Fort Collins CO, US
Kevin S. Brandt - Fort Collins CO, US

Assignee:

Heska Corporation - Loveland CO

International Classification:

C12N 9/02
C12N 1/20
C12N 15/00
C12Q 1/00
C12Q 1/68
C12Q 21/04
C07H 21/04

US Classification:

435189, 435 4, 435 6, 435440, 435 691, 435 711, 4352523, 4353201, 536 232, 536 235

Abstract:

The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.

US Patent:

7419793, Sep 2, 2008

Filed:

Jul 11, 2003

Appl. No.:

10/521162

Inventors:

Kevin S. Brandt - Longmont CO, US

Assignee:

Heska Corporation - Loveland CO

International Classification:

G01N 33/566
C07H 21/04
C07K 14/705

US Classification:

435 72, 536 235, 530350, 530858

Abstract:

The present invention relates to tick octopamine receptor nucleic acid molecules; to tick octopamine receptor proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes inhibitory compounds, particularly those that specifically inhibit tick octopamine receptor activity, as well as the use of such compounds to treat animals.

US Patent:

7476524, Jan 13, 2009

Filed:

Mar 10, 2006

Appl. No.:

11/372770

Inventors:

Nancy Wisnewski - Fort Collins CO, US
Kevin S. Brandt - Fort Collins CO, US

Assignee:

Heska Corporation - Loveland CO

International Classification:

C12N 9/02
C12N 1/20
C12N 15/00
C12P 21/04
C12Q 1/68
C07H 21/02
C07H 21/04
C12Q 1/00
C12Q 1/26

US Classification:

435189, 435 4, 435 6, 435 25, 435 691, 435 711, 4352523, 4353201, 435440, 536 231, 536 232

Abstract:

The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.

US Patent:

7476728, Jan 13, 2009

Filed:

Nov 21, 2002

Appl. No.:

10/433140

Inventors:

Nancy Wisnewski - Fort Collins CO, US
Kevin S. Brandt - Fort Collins CO, US

Assignee:

Heska Corporation - Loveland CO

International Classification:

C07H 21/02

US Classification:

536 231

Abstract:

The present invention relates to flea GABA receptor subunit nucleic acid molecules; to flea GABA receptor subunit proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and inhibitory compounds, particularly those that specifically inhibit flea GABA receptor subunit activity, as well as the use of such therapeutic compositions to treat animals.

US Patent:

7666641, Feb 23, 2010

Filed:

Jan 12, 2009

Appl. No.:

12/352511

Inventors:

Nancy Wisnewski - Fort Collins CO, US
Kevin S. Brandt - Fort Collins CO, US

Assignee:

Heska Corporation - Loveland CO

International Classification:

C12N 9/02
C12P 21/04
C12N 1/20
C12N 15/00
C12Q 1/68
C07H 21/02
C07H 21/04
C12Q 1/00
C12Q 1/26

US Classification:

435189, 435 4, 435 6, 435 25, 435 691, 435 711, 4352523, 4353201, 435440, 536 231, 536 232

Abstract:

The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.

Address:

64 Stanford Ln, Longmont, CO 80503

Phone:

970 402-8946

VIN:

5NPDH4AE4CH119933

Make:

HYUNDAI

Model:

ELANTRA

Year:

2012